Effect of new mono- and bi-specific somatostatin analogue (SSA) compunds and effect of SS/DA chim...
Medical treatment of neuroendocrine tumors (NETs) and pituitary adenomas provides for the use of somatostatin and dopamine analogs (SSAs, DAs) due to the characteristic of these tumors to express specific receptors for both peptides (SSRs and DRs).
Depending on the receptor expression profile, this study will evaluate the role of new mono- and bi-specific SSA compounds as well as SS/DA chimeric compounds on hormonal secretion and cell proliferation in primary cultures of post-surgical NETs and functioning and non-functioning pituitary adenomas.
Moreover, the study will evaluate the in vivo anti-angiogenetic and anti-migratory effects of all compounds in the zebrafish embryo animal model expressing fluorescent endothelial cells after injection of post-surgical tumor cells followed by embryo treatment with sperimental compounds.
This job comes from a partnership with Science Magazine and